Nexten Bioscience "No Issues in Business Progress"
[Asia Economy Reporter Jang Hyowon] Nexten Bioscience posted a statement on its website on the 18th regarding the sharp decline in its stock price.
The company stated, "As already announced through a press release, the CNC precision machinery division's performance improved compared to the same period last year," and added, "In the bio division, we signed an MOU with China Donghua Dongbao Pharmaceutical for the development of diabetes treatments and are currently in discussions with leading global pharmaceutical companies for diabetes treatment development."
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
- "Am I Really in the Top 30%?" and "Worried About My Girlfriend in the Bottom 70%"... Buzz Over High Oil Price Relief Fund
- "It Has Now Crossed Borders": No Vaccine or Treatment as Bundibugyo Ebola Variant Spreads [Reading Science]
They continued, "We will inform shareholders once related matters are finalized, and there is no change to the company's core essence at present," and concluded, "All company executives and employees will do their best to achieve growth and enhance shareholder value."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
